A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

ClinicalTrials.gov ID: NCT02045732

Public ClinicalTrials.gov record NCT02045732. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 27, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS. PF-06342674 (RN168) is expected to play a role in slowing down the progression of the disease.

Study identification

NCT ID: NCT02045732
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Pfizer; Industry
Enrollment: 4 participants

Conditions and interventions

Conditions

Multiple Sclerosis

Interventions

Biological

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2014
Primary completion: Sep 30, 2015
Completion: Sep 30, 2015
Last update posted: Jan 15, 2017

2014 – 2015

United States locations

U.S. sites: 8
U.S. states: 3
U.S. cities: 5

Facility	City	State	ZIP	Site status
Albany Advanced Imaging	Albany	New York	12205	—
Fallon Wellness Pharmacy	Latham	New York	12110	—
Northeast Eye Center	Latham	New York	12110	—
The MS Center of Northeastern New York	Latham	New York	12110	—
Cleveland Clinic	Cleveland	Ohio	44195	—
Retina Vitreous Center	Edmond	Oklahoma	73013	—
Lynn Health Science Institute	Oklahoma City	Oklahoma	73112	—
Radiology Associates (X-ray facility only)	Oklahoma City	Oklahoma	73112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02045732, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 15, 2017 · Synced Sep 27, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02045732 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →